In this issue:
- Pembrolizumab + chemotherapy in advanced endometrial cancer
- Dostarlimab + chemotherapy in primary advanced/recurrent endometrial cancer
- Neoadjuvant chemotherapy & subsequent debulking surgery in metastatic endometrial cancer
- Vaginal/sexual functioning problems & distress in cervical cancer survivors
- Locoregional therapy for oligometastatic cervical cancer
- HPV self-sampling kits to increase participation in cervical cancer screening
- Lenvatinib + pembrolizumab in previously treated advanced endometrial cancer
- Delay/avoidance in care & financial toxicity in BRCA1/2 carriers
- Olaparib + bevacizumab first-line maintenance in ovarian cancer
- Mirvetuximab soravtansine in platinum-resistant ovarian cancer with high FRα expression
Please login below to download this issue (PDF)